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Abstract: Gastrointestinal stimulator implants have
recently shown promising results in helping obese patients
lose weight. However, to place the implant, the patient cur-
rently needs to undergo an invasive surgical procedure.
We report a less invasive procedure to stimulate the stom-
ach with a gastrostimulator. After attempting fully endo-
scopic implantation, we more recently focused on a single
incision percutaneous procedure. In both cases, the
challenges in electronic design of the implant are largely
similar. This article covers the work achieved to meet these
and details the in vivo validation of a gastrostimulator
aimed to be endoscopically placed and anchored to the
stomach. Key Words: Obesity—Gastric electrical stim-
ulation—Implanted gastric stimulator—Design and
implementation—In vivo validation.
Obesity is a pandemic of 21st Century with 2.1
billion overweight adults (body mass index [BMI]
above 25) and 600 million obese adults (BMI above
30) worldwide (1–3). Obesity is commonly associ-
ated with major health problems, and each year it
is responsible for millions of deaths (2–4). Bariatric
surgery can be efficient in dealing with this issue
but these are invasive operations, performed either
by multi-incision laparoscopy or even open surgery.
Besides, they represent a large portion of annual
healthcare expenditures and are limited to patients
whose BMI is over 35 (5). Gastrostimulation has
been demonstrated to induce weight loss in humans
(6–8). However, current gastrostimulators are bulky
and are implanted by multi-incision laparoscopy, a
relatively expensive and invasive procedure. Our
aims are to develop a new generation of smaller
implants, which can be located in a less invasive
manner. We have worked on a first design suitable
for a fully endoscopic placement, and more recently
we have investigated a design for a single-incision
laparoscopic procedure. Whatever the chosen
implantation solution, the electronic design of these
gastrostimulators presents many challenges. From
an engineering point of view, compared to cur-
rently available stimulators, we aim to:
! reduce the dimensions and weight of the
device while protecting it from its
environment,
! provide a stable anchoring,
! provide a reliable implantation method to
place and attach the device.
This article presents the design and implementa-
tion of these novel gastrostimulators. It details the
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in vivo validation of a gastrostimulator aimed to be
endoscopically implanted. The design and imple-
mentation of the gastrostimulator, the test-bench
and ex vivo validation have been detailed in a pre-
vious publication (9).
MATERIALS AND METHODS
Electronic and mechanical design
The stimulation protocol is based on that of the
Enterra device by Medtronic, which has already
achieved good results with electrodes near the pylo-
rus in humans (7,8), and at the pylorus in dogs (10).
The protocol consists in sending trains of current
pulses for 2 s every 5 s. Each train is composed of 5
mA pulses, lasting 330 ls, repeated at 40 Hz. Figure
1 shows a block diagram of our implant, including a
non-rechargeable battery, a voltage boost (to feed
the stimulator with a voltage higher than the 3.5 V
of the battery), a microcontroller lC (for the timing
and circuit synchronization) and the stimulation cir-
cuit. Briefly, the current source is based upon an
operational amplifier driving the gate of a MOS
transistor (5LN01) biased in its pinch-off region
(i.e., where it behaves like a voltage-controlled cur-
rent source). A microcontroller (PIC10LF322) is
used to switch the amplifier (MAX9911) ON and
OFF to obtain the desired stimulation pattern. In
this first prototype, power is supplied by a single
battery cell whose voltage is too low and varies
along the discharge. A voltage boost (LT3464) is
used to provide a higher and constant voltage to
the stimulation circuit. The battery directly powers
the microcontroller and the operational amplifier.
The use of a non-rechargeable battery has been
preferred in this work. It allowed the conception of
a first prototype, with a battery life sufficient for the
first experiments. A button cell (CR2032) suitable
for endoscopic implantation in terms of weight (only
2.9 g) and dimensions (20 mm diameter and 3.2 mm
height) has been used. Its capacity reaches 220 mAh
and its minimum operating voltage fits well those of
the op amp, boost, and microcontroller.
We expect in situ impedance ranging from 200 to
800 X (11–15). A 2.2 lF blocking capacitor ensures
a null mean charge (16). A depletion transistor
(LND150) is used to limit the discharge current to
at most 20% of the stimulation current. During the
stimulation phase, the depletion transistor is
blocked and the current goes through the electro-
des. During the discharge period, the capacitor dis-
charges through the electrodes (hence the stomach
wall) and the depletion transistor.
The circuit fits on a 16-mm diameter substrate.
The site of the pyloric sphincter was chosen to
anchor the device. The implant is composed of two
cylinders linked by a flexible coil. It is designed to
be endoscopically placed, with a cylinder on either
side of the pylorus. One cylinder hosts the electron-
ics and electrodes to deliver the stimulation (see
Fig. 2). The other one contains the battery. Surface
recessed electrodes have been chosen to ensure a
good contact between the electrodes and the tissue.
This also allows a good uniformity of the electric
field (17,18). These electrodes are designed to 3 3
3 mm, separated by 2 mm. Their size is based on
the available space, choosing them as large as possi-
ble to ensure the best contact with the tissue. This
also helps to limit the electrode current density and
prevents irreversible electro-chemical reactions
(19).
Choice of materials
To minimize the device’s overall weight and vol-
ume, we have opted to protect the electronics by
encapsulation (i.e., coating) with silicone rubber.
The silicone rubber prevents the circuit from
ingress of fluids and protects the body from implant
contamination. Silicone encapsulation is used in
commercial applications and gives implant lifetimes
FIG. 1. Block diagram of the implant.
FIG. 2. Anchoring of the implant at the pyloric sphincter.
L. LONYS ET AL.E214
Artif Organs, Vol. 41, No. 11, 2017
of several decades (20). It was briefly reviewed by
Vanhoestenberghe and Donaldson (21). When the
implant is placed in the stomach, this protective
layer should resist its acidic environment. This
method is well established for human implants (20),
but has never been used for devices operating in
the stomach, where the very low pH presents a new
challenge. The success of this protection relies on
the long-term stability of the bond between the
encapsulant and the substrate on which the circuit
is built (22). Therefore, several couples of substrate
and adhesive were tested following Donaldson’s
method (23).
The long-term stability of the adhesive bond
between several couples of substrate and adhesive
immersed in simulated gastric liquid was the topic
of a previous publication (24). For this animal
study, an FR4 substrate was chosen with MED4–
4220 silicone rubber (9).
Manufacturing of the implant
The printed circuits were ordered from Eurocir-
cuits. The substrate was made of FR4, and the sur-
face electrodes and electronic tracks were printed
in copper.
Cleanliness during the encapsulation process
strongly influences the implant’s lifetime (22).
Briefly, the cleaner the circuit and the substrate,
the higher the osmotic gradient, should water
vapor, which will rapidly permeate the encapsula-
tion layer, find a condensation site. Liquid water
formation would therefore be limited, and what
would form would be highly resistive, hence limit-
ing further loss of adhesion and corrosion. There-
fore, the devices were thoroughly cleaned using
isopropanol and an alkaline cleaning solution, and
even more thoroughly rinsed in flowing de-ionized
water. A dedicated mold was built to encapsulate
the implant. The design of the mold allows a pro-
tection layer of silicone rubber of 2 mm on the
components side and of 0.5 mm on the other side.
The encapsulation was realized using a vacuum
centrifuge. The design of the mold allows the 3 3
3 mm surface electrodes to remain uncovered by
silicone rubber and hence recessed within a 0.5 mm
silicone layer (see Fig. 3). The encapsulated
implant, which is 17 mm diameter and 5.5 mm
thick, is small enough to allow endoscopic passage
through the mouth.
The battery was dip-coated with Dow Corning
3140 silicone rubber and the procedure was
repeated until the layer of the silicone rubber was
sufficiently thick to cover all the sharp edges. Each
new layer of silicone rubber was degassed and dried
before the next dip. DC3140 was selected for dip-
coating as it forms a thin layer and dries in a few
minutes in a humid environment at room tempera-
ture. This silicone rubber is, however, not autho-
rized for human implantation. It was used only for
this prototyping stage and no adhesion tests were
performed between DC3140 and the material of
the battery case. Dacron meshes were added to the
battery cell helping the surgeon attach the two
parts with sutures.
Low temperature gas plasma technology steriliza-
tion (Sterrad) was used for the implant and the bat-
tery, avoiding a potential degradation of the
battery. Steam sterilization was used for all the
material not based on silicone rubber, and for the
plug connectors to the data acquisition system and
the silver electrodes.
Figure 3 shows the resulting implant.
Animal preparation and experimental protocol
Three male beagles were used for this study. The
surgical and experimental protocols were approved
FIG. 3. Illustration of the implant
(17 mm diameter and 5.5 mm
height) and its two square
electrodes.
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by the Animal Care and Use Committee of the
Universit!e de Lie`ge.
Dogs were fasted for 24 h before the implanta-
tion. They were maintained under general anesthe-
sia with propofol and isoflurane. During the
implantation, heart rate and breathing rate of the
dogs were monitored.
The procedure aimed to surgically implant in the
stomach and validate a gastrostimulator that subse-
quently could be endoscopically placed and
anchored to the stomach. This way, the assessment
of the gastrostimulator (stomach stimulation, resis-
tance to stomach environment, anchoring, and non-
invasive monitoring) could be performed while
eliminating technical difficulties of endoscopic
placement.
The implantations lasted between 60 and 90 min.
The procedure started with the incision of the cuta-
neous layer, the muscular aponeurosis, the muscle,
and the peritoneum, followed by the dissection of
the greater omentum until the pre-pyloric antrum
and then the incision of the pylorus. The stimulating
part of the implant was first transmurally inserted in
the pylorus to reflect the intended position, that is,
when the gastrostimulator will be endoscopically
placed. During the implantation, the battery cell was
considered too cumbersome for implantation in the
duodenum and was instead transmurally inserted in
the pre-pyloric antrum, to limit the likelihood of
bowel obstruction. Before closing the skin, pulses
were measured to validate the implant proper posi-
tion. Then, the surgeon sutured the mucosa and the
serosa (i.e., the stomach is sutured), the peritoneum
serosa, the muscle layer, and the cutaneous layer
(i.e., the skin is sutured). The dogs were returned to
their cage right after the implantation, showing no
sign of health problems.
To monitor the in vivo activity of the implant,
two different methods of measurements were used,
with either serosal or cutaneous electrodes. The fol-
lowing material was used:
! an electrophysiological data acquisition system
(BIOPAC MP150 data acquisition system),
including an electromyogram amplifier
(EMG100C);
! cutaneous electrodes (3M EL510);
! homemade 20 mm needle electrodes built
from silver wire (ALFA AESAR silver wire,
0.5 mm, 99,9985%).
For both methods of measurements, the data
acquisition system was configured to record the
propagation of the stimulation pattern (with a 1 Hz–
5 kHz bandpass and a 50k sample/s sampling rate).
This way, we could assess that the stimulator pulses
were properly delivered to the stomach. Please note
that we were therefore not focusing at this stage on
the physiological effect induced by the stimulation.
Before closing the skin, intramuscular data were
acquired using the electromyogram amplifier mod-
ule. Needle electrodes were inserted in the muscular
layer, penetrating the serosa near the stimulation
site to validate the position of the implant and the
contact with the stomach. Recording electrodes
were then removed and after closing the skin, the
stimulation was recorded using surface electrodes.
These electrodes were connected directly to the
electromyogram amplifier module. After the day of
the implantation (Day D), endoscopies and radios-
copies were performed to monitor the implant
anchoring and internal response of the dogs.
The monitoring procedure is illustrated in Fig. 4.
RESULTS
The implant main characteristics were first
assessed on a test bench and ex vivo before in vivo
validation (9).
FIG. 4. Two monitoring methods.
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Stimulation protocol and load range
To validate the stimulation protocol, an implant
was used in continuous mode (trains repeated with-
out interruption) with a purely resistive load vary-
ing between 200 and 1400 X. For load values up to
1200 X, we verified that the implant delivered 5
mA pulses, 330 ms wide repeated at 40 Hz and a
complete discharge. The trains lasted 2 s and are
repeated every 5 s, giving 12 bursts per minute. Fig-
ure 5 shows two successive trains of pulses (blue
curve) and the power supply voltage (green curve).
From 1400 X, the stimulation waveform was
affected, with lower stimulating current. Also, due
to the saturation of the operational amplifier,
slightly longer pulses were observed.
Power requirement
The output stage includes a boost DC/DC con-
verter to increase the battery voltage (around 3.3
V) to the 8 V required for the stimulation. The cho-
sen boost (LT3464) uses a discontinuous mode.
1. Output stage consumption (stimulation phase)
Figure 6 shows that during a stimulation
pulse, the instantaneous current from the bat-
tery reached peaks of 75 mA, repeated at
11 kHz. The boost was working in a discontin-
uous mode, as expected. Therefore, during
pulse delivery, an average current of 16 mA
was drawn from the battery (see red curve on
Fig. 6).
2. Output stage consumption (quiet phase)
Figure 7 shows that in the quiet phase the
instantaneous current consumption of the
boost also reached peaks up to 75 mA, but
only repeated at 20 Hz. This frequency is
lower than during a stimulation pulse
(11 kHz), since the implant was in quiet phase
and hence the current consumption was lower.
3. Implant consumption and lifetime
The total average current of the implant was 370
mA. With an output voltage of 3.5 V (directly mea-
sured at the battery output) the battery delivered a
power of 1.295 mW. The output voltage and output
current of the implant are respectively 8 V and 26
mA, hence the useful power delivered was 208 mW,
leading to an efficiency of 16% for the whole
system.
The choice of a CR2032 battery cell corresponds
to a 27-day lifetime. Note that commercially
FIG. 5. Monitoring of the pulses train. FIG. 6. Current peaks and average current consumed during
stimulation: the green curve is the input voltage of the amplifier;
the blue curve represents the instantaneous current consump-
tion and red curve is the average current consumption com-
puted over the current peaks.
FIG. 7. Output voltage of the boost (blue curve) and current
consumption (green curve) during quite phase.
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biocompatible available batteries from EaglePicher,
Greatbach, Quallion, and Saft were considered and
we found energy densities no higher than 1595
mWh/cm3. Using this kind of battery, the implant
lifetime would reach 51 days per cubic centimeter.
Minimum required voltage
Figure 8 shows the behavior of the implant when
the battery voltage decreased due to its discharge.
When the battery voltage felt below 2.1 V no pulse
was delivered anymore. At 2.1 V, the microcontrol-
ler was not able to deliver the desired output val-
ues. At 2 V, the boost was no longer working. The
implant stopped working without displaying any
erratic behavior likely to induce damage.
In vivo validation
Three dogs were surgically implanted with the
stimulator (Day D) to evaluate its functionality and
the propagation of the stimulation. The durability
of the anchoring method was also assessed during
the experiment.
Figure 9 shows the serosal measurements on the
day of the implantation (Day D) in one of the dogs
(dog #2). Figure 9 confirms that the stomach was
stimulated with trains delivered at the intended fre-
quency. However, the impedance of the tissue
could not be verified because of the saturation of
the monitoring data acquisition station and the
presence of fluid.
Figure 10 shows the cutaneous measurements on
the day of the implantation (Day D) in one of the
FIG. 8. Effect of the decrease of the battery cell voltage (pur-
ple) on the stimulation (blue) and the boost voltage (red).
FIG. 9. Serosal measurements of the stimulation on the day of
implantation (Day D).
FIG. 10. Cutaneous measurements of the stimulation on the
day of implantation (same dog, Day D).
FIG. 11. Control endoscopy 1 week after the day of implanta-
tion (Day D17).
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dogs (dog #2). Stimulation was successfully moni-
tored and the intended frequency of the trains was
observed.
Figure 11 shows an endoscopic view of the
implant in the same dog 1 week after implantation
(Day D1 7).
The monitoring was performed as detailed in
Table 1. Control postoperative radiographies were
performed on Day D1 1 and D1 7 on the three
dogs. In the three dogs, radiographies on D1 1 con-
firm the position of the implant and the battery cell
in their initial implantation site. On D1 6, no electri-
cal activity could be measured using cutaneous elec-
trodes in any dogs, indicating either that the implant
had stopped stimulating or that it had migrated.
Endoscopies and radiographies performed on
D1 7 showed:
! migration in the duodenum of the stimulation
part in dog #1 and a potential failure of the
electrical wire,
! no migration but a potential failure of the con-
nection between the two parts of the implant
in dog #3,
! that the electrical wire came out of its encap-
sulant on dog #2,
No health problems were detected in dog #2 and
dog #3. In dog #1, the stimulating part and the bat-
tery cell were retrieved in the stool at D1 12 and
D1 42. Post procedure observations of this implant
suggest early failure of the adhesion on the side
of the ground plane. Early failure could come from
the weaker adhesion between silicone rubber and
the copper used for the ground plane needed by the
boost. The stimulating part of the implant, which was
retrieved alone in the stool, was tested after the end
of the procedure. It was powered by a regulated sup-
ply voltage, but was not operational anymore, mean-
ing no stimulation waveform was observed between
the electrodes. Further, no indication of the polarity
of the connection to the power supply was available
on the implant and this could also have damaged the
implant when testing it after the procedure.
DISCUSSION AND CONCLUSIONS
We presented the design and implementation of
a gastrostimulator, with reduced dimensions and
weight. The device function was first validated on a
test bench and ex vivo before in vivo validation in
three beagles.
Today, commercial gastrostimulators are derived
from the bulky hermetically sealed cardiac pace-
makers, hence not allowing endoscopic implanta-
tion and durable anchoring at the pylorus. One
team has developed an endoscopically implantable
gastrostimulator (12). However, they have chosen a
voltage stimulator for their design and the device
was removed after 2 h in vivo and no information
regarding long-term adhesion, or general efficiency
of the protection method, could be deduced (12).
Our stimulator was specifically designed to stimu-
late the stomach. The size and weight of the stimu-
lator were designed to allow endoscopic
implantation and durable anchoring. A current
source was chosen to ensure a controlled stimulat-
ing current through the tissue and an adequate cou-
ple silicone rubber/substrate was chosen to protect
the device from the acidic environment (24). Sur-
face embedded electrodes were able to deliver the
stimulation pulses at the intended frequency. The
implant is based on discrete commercially available
components. A noninvasive recording method was
introduced and validated to monitor the function-
ing of the implant.
The stimulation was successfully monitored using
cutaneous electrodes. To the best of our knowl-
edge, this has not been reported in the literature.
Other groups have traditionally monitored the
response to their implants using endoscopically
placed electrodes (25,26).
Our first prototype shows a lifetime of 27 days.
Quiescent currents are responsible for a large part
of the discharge of the battery. The components
TABLE 1. Schedule of the dogs’ follow-ups
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could be—and indeed were in subsequent versions
of the implant developed by our group—set in
sleep mode during the idle phases. This reduces by
half its average consumption and extend the life-
time to 80 days. Yet, other powering solutions are
required to reach a long-term treatment and to
compete with alternatives such as the gastric bal-
loon. Our team has developed a wireless powering
and communication system, able to power an endo-
scopic implant, and improve its lifetime.
In this work, the electronic circuit of the proto-
type was supplied by Eurocircuits. It allows fast
prototyping with traditional materials for the sub-
strate and the electronic tracks. FR4 with MED4–
4220 allows a sufficient lifetime of adhesion for a
short-term validation, but for long-term use, FR4
should be replaced by alumina, which offers the
longest lifetime with MED4–4220. Further, the
encapsulation quality is also influenced by the
adhesion with the IC’s, the solder, and the copper
used for the electronic tracks. A weaker adhesion
was, for example, observed between the ground
plane and the silicone rubber. Platinum gold could
for example replace copper for electronic tracks.
Further work will include the improvement of
the connection between the two parts of the
implant using a more robust cable, and improving
the anchoring method to avoid migration. A new
minimally invasive surgical implantation method is
also currently under investigation. These implants
will include new features such as a wireless commu-
nication system. It is of primary importance since it
allows to dynamically adapt the stimulation pattern
and to monitor the functioning of the implant. The
next prototype will therefore be able to stimulate
only around mealtime and to prevent the stomach
from accommodating to the stimulation. Future
tests aim to assess the effect of the gastric stimula-
tion in vivo. Active stimulators will be implanted in
dogs to assess the weight loss during stimulation.
Different stimulation protocols will be tested dur-
ing the experiment. The impact on the gastric slow
waves, specific hormones, and the amount of food
ingested will be monitored to assess the physiologi-
cal impact of the selected stimulation protocol.
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